Literature DB >> 17306536

Ribonuclear foci at the neuromuscular junction in myotonic dystrophy type 1.

T M Wheeler1, M C Krym, C A Thornton.   

Abstract

In myotonic dystrophy type 1 (DM1) the muscle fibers express RNA containing an expanded CUG repeat (CUG(exp)). The CUG(exp) RNA is retained in the nucleus, forming ribonuclear foci. Splicing factors in the muscleblind (MBNL) family are sequestered in ribonuclear foci, resulting in abnormal regulation of alternative splicing. In extrajunctional nuclei, these effects on splicing regulation lead to reduced chloride conductance and altered insulin receptor signaling. Here we show that CUG(exp) RNA is also expressed in subsynaptic nuclei of muscle fibers and in motor neurons in DM1, causing sequestration of MBNL1 protein in both locations. In a transgenic mouse model, expression of CUG(exp) RNA at high levels in extrajunctional nuclei replicates many features of DM1, but the toxic RNA is poorly expressed in subsynaptic nuclei and the mice fail to develop denervation-like features of DM1 myopathology. Our findings indicate that subsynaptic nuclei and motor neurons are at risk for DM1-induced spliceopathy, which may affect function or stability of the neuromuscular junction.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17306536      PMCID: PMC2752326          DOI: 10.1016/j.nmd.2006.12.015

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  36 in total

Review 1.  Targeting transcription to the neuromuscular synapse.

Authors:  L Schaeffer; A de Kerchove d'Exaerde; J P Changeux
Journal:  Neuron       Date:  2001-07-19       Impact factor: 17.173

Review 2.  Localizing synaptic mRNAs at the neuromuscular junction: it takes more than transcription.

Authors:  Joe V Chakkalakal; Bernard J Jasmin
Journal:  Bioessays       Date:  2003-01       Impact factor: 4.345

3.  Axonopathy and amyotrophy in mice transgenic for human four-repeat tau protein.

Authors:  A Probst; J Götz; K H Wiederhold; M Tolnay; C Mistl; A L Jaton; M Hong; T Ishihara; V M Lee; J Q Trojanowski; R Jakes; R A Crowther; M G Spillantini; K Bürki; M Goedert
Journal:  Acta Neuropathol       Date:  2000-05       Impact factor: 17.088

4.  Dysregulation of human brain microtubule-associated tau mRNA maturation in myotonic dystrophy type 1.

Authors:  N Sergeant; B Sablonnière; S Schraen-Maschke; A Ghestem; C A Maurage; A Wattez; P Vermersch; A Delacourte
Journal:  Hum Mol Genet       Date:  2001-09-15       Impact factor: 6.150

5.  Myotonic dystrophy in transgenic mice expressing an expanded CUG repeat.

Authors:  A Mankodi; E Logigian; L Callahan; C McClain; R White; D Henderson; M Krym; C A Thornton
Journal:  Science       Date:  2000-09-08       Impact factor: 47.728

6.  Muscleblind proteins regulate alternative splicing.

Authors:  Thai H Ho; Nicolas Charlet-B; Michael G Poulos; Gopal Singh; Maurice S Swanson; Thomas A Cooper
Journal:  EMBO J       Date:  2004-07-15       Impact factor: 11.598

7.  A muscleblind knockout model for myotonic dystrophy.

Authors:  Rahul N Kanadia; Karen A Johnstone; Ami Mankodi; Codrin Lungu; Charles A Thornton; Douglas Esson; Adrian M Timmers; William W Hauswirth; Maurice S Swanson
Journal:  Science       Date:  2003-12-12       Impact factor: 47.728

8.  Quantitative analysis of the human alpha-skeletal actin gene in transgenic mice.

Authors:  K J Brennan; E C Hardeman
Journal:  J Biol Chem       Date:  1993-01-05       Impact factor: 5.157

9.  Expanded CUG repeats trigger aberrant splicing of ClC-1 chloride channel pre-mRNA and hyperexcitability of skeletal muscle in myotonic dystrophy.

Authors:  Ami Mankodi; Masanori P Takahashi; Hong Jiang; Carol L Beck; William J Bowers; Richard T Moxley; Stephen C Cannon; Charles A Thornton
Journal:  Mol Cell       Date:  2002-07       Impact factor: 17.970

10.  Loss of the muscle-specific chloride channel in type 1 myotonic dystrophy due to misregulated alternative splicing.

Authors:  Nicolas Charlet-B; Rajesh S Savkur; Gopal Singh; Anne V Philips; Elizabeth A Grice; Thomas A Cooper
Journal:  Mol Cell       Date:  2002-07       Impact factor: 17.970

View more
  22 in total

Review 1.  Myotonic dystrophy mouse models: towards rational therapy development.

Authors:  Mário Gomes-Pereira; Thomas A Cooper; Geneviève Gourdon
Journal:  Trends Mol Med       Date:  2011-07-02       Impact factor: 11.951

Review 2.  Modeling diseases of noncoding unstable repeat expansions using mutant pluripotent stem cells.

Authors:  Shira Yanovsky-Dagan; Hagar Mor-Shaked; Rachel Eiges
Journal:  World J Stem Cells       Date:  2015-06-26       Impact factor: 5.326

Review 3.  Myotonic dystrophy: approach to therapy.

Authors:  Charles A Thornton; Eric Wang; Ellie M Carrell
Journal:  Curr Opin Genet Dev       Date:  2017-04-01       Impact factor: 5.578

Review 4.  Regulatory RNAs in brain function and disorders.

Authors:  Anna Iacoangeli; Riccardo Bianchi; Henri Tiedge
Journal:  Brain Res       Date:  2010-03-20       Impact factor: 3.252

5.  A novel CUG(exp)·MBNL1 inhibitor with therapeutic potential for myotonic dystrophy type 1.

Authors:  Amin Haghighat Jahromi; Lien Nguyen; Yuan Fu; Kali A Miller; Anne M Baranger; Steven C Zimmerman
Journal:  ACS Chem Biol       Date:  2013-03-20       Impact factor: 5.100

6.  Transcriptional and post-transcriptional impact of toxic RNA in myotonic dystrophy.

Authors:  Robert J Osborne; Xiaoyan Lin; Stephen Welle; Krzysztof Sobczak; Jason R O'Rourke; Maurice S Swanson; Charles A Thornton
Journal:  Hum Mol Genet       Date:  2009-02-17       Impact factor: 6.150

7.  Splicing biomarkers of disease severity in myotonic dystrophy.

Authors:  Masayuki Nakamori; Krzysztof Sobczak; Araya Puwanant; Steve Welle; Katy Eichinger; Shree Pandya; Jeannne Dekdebrun; Chad R Heatwole; Michael P McDermott; Tian Chen; Melissa Cline; Rabi Tawil; Robert J Osborne; Thurman M Wheeler; Maurice S Swanson; Richard T Moxley; Charles A Thornton
Journal:  Ann Neurol       Date:  2013-12       Impact factor: 10.422

Review 8.  Myotonic dystrophy: therapeutic strategies for the future.

Authors:  Thurman M Wheeler
Journal:  Neurotherapeutics       Date:  2008-10       Impact factor: 7.620

9.  Molecular Effects of the CTG Repeats in Mutant Dystrophia Myotonica Protein Kinase Gene.

Authors:  Beatriz Llamusí; Ruben Artero
Journal:  Curr Genomics       Date:  2008-12       Impact factor: 2.236

10.  Functional and histopathological identification of the respiratory failure in a DMSXL transgenic mouse model of myotonic dystrophy.

Authors:  Petrica-Adrian Panaite; Thierry Kuntzer; Geneviève Gourdon; Johannes Alexander Lobrinus; Ibtissam Barakat-Walter
Journal:  Dis Model Mech       Date:  2012-11-23       Impact factor: 5.758

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.